{
 "metadata": {
  "title": "Patient Assistance Program Eligibility by Drug 2026: What Each Drugmaker Publishes, Read on the Sponsor's Own Page",
  "slug": "patient-assistance-eligibility-2026",
  "edition": "2026-10-29",
  "readDate": "2026-10-29",
  "license": "CC-BY-4.0",
  "publisher": "OmniRx",
  "domain": "omnirx.org",
  "creator": "DeepSynthesis",
  "version": "1.1",
  "versionDate": "2026-10-30",
  "doi": "10.5281/zenodo.23812709",
  "conceptDoi": "10.5281/zenodo.23787926",
  "versionHistory": [
   {
    "version": "1.0",
    "date": "2026-10-29",
    "note": "First publication: 32 rows, 18 read, 3 not-published, 7 not-listed, 4 blocked."
   },
   {
    "version": "1.1",
    "date": "2026-10-30",
    "note": "Three blocked rows read on 2026-10-30: Symbicort and Brilinta are not on the AZ&Me medications page (now not-listed); Humira is on the AbbVie available-programs list and takes the same income table as Skyrizi (now read). v1.0 had Humira blocked because only the returning-patient list had been opened. 19 read, 3 not-published, 9 not-listed, 1 blocked (Pfizer Eliquis)."
   }
  ],
  "protocolSha256": "519cbab87e85037d11060b9483e462d6cbe8ceb9601691406fd89096b10adddc",
  "protocolFrozen": "2026-10-29",
  "amendments": [
   {
    "date": "2026-10-29",
    "madeAfterFirstRead": true,
    "change": "Added incomeRule code 'exempt' and the field evidenceMethod.",
    "reason": "Bristol Myers Squibb states that its cancer, ulcerative colitis, multiple sclerosis, plaque psoriasis, obstructive hypertrophic cardiomyopathy and kidney transplant medicines qualify even above the listed income limits. None of the frozen codes could say that without misreporting it as 'none-published'. Several sponsor documents are PDFs with no text layer, so a text hash is impossible for them; evidenceMethod records how each row was read.",
    "effect": "Only the BMS cancer rows use the new income code. The drug set, sponsors and rules are unchanged."
   }
  ],
  "unit": "one row per drug x sponsor program, read on the sponsor's own page in Chrome",
  "guideline": {
   "year": 2026,
   "region": "48 contiguous states and DC",
   "person1": 15960,
   "perExtra": 5680,
   "source": "https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines",
   "readDate": "2026-10-29"
  },
  "scope": "Published rules as read on the sponsor's own page on the read date. Not an eligibility determination, medical advice or financial advice."
 },
 "headlines": {
  "rows": 32,
  "drugs": 31,
  "sponsors": 13,
  "byStatus": {
   "read": 19,
   "not-published": 3,
   "not-listed": 9,
   "blocked": 1
  },
  "sponsorsRead": 9,
  "sponsorsWithLimit": 9,
  "oneLimitMin": 31920,
  "oneLimitMax": 79800,
  "rowsWithLimit": 18,
  "testCase": {
   "income": 55000,
   "clears": 6,
   "fails": 12,
   "rowsWithLimit": 18,
   "unknown": 14,
   "note": "one-person limits only; insurance and Medicare rules decide separately whether the program is open to the person at all"
  },
  "demandedWithLimit": 4,
  "demandedTotal": 7,
  "demanded": [
   {
    "drug": "Ozempic",
    "rows": [
     {
      "sponsor": "Novo Nordisk",
      "status": "not-published",
      "dollars1": null,
      "fplPct": null
     }
    ],
    "anyLimit": false
   },
   {
    "drug": "Wegovy",
    "rows": [
     {
      "sponsor": "Novo Nordisk",
      "status": "not-listed",
      "dollars1": null,
      "fplPct": null
     }
    ],
    "anyLimit": false
   },
   {
    "drug": "Trelegy Ellipta",
    "rows": [
     {
      "sponsor": "GSK",
      "status": "read",
      "dollars1": 47880,
      "fplPct": null
     }
    ],
    "anyLimit": true
   },
   {
    "drug": "Farxiga",
    "rows": [
     {
      "sponsor": "AstraZeneca",
      "status": "not-listed",
      "dollars1": null,
      "fplPct": null
     }
    ],
    "anyLimit": false
   },
   {
    "drug": "Eliquis",
    "rows": [
     {
      "sponsor": "Bristol Myers Squibb",
      "status": "read",
      "dollars1": 47880,
      "fplPct": null
     },
     {
      "sponsor": "Pfizer",
      "status": "blocked",
      "dollars1": null,
      "fplPct": 300
     }
    ],
    "anyLimit": true
   },
   {
    "drug": "Jardiance",
    "rows": [
     {
      "sponsor": "Boehringer Ingelheim",
      "status": "read",
      "dollars1": 39900,
      "fplPct": 250
     }
    ],
    "anyLimit": true
   },
   {
    "drug": "Repatha",
    "rows": [
     {
      "sponsor": "Amgen",
      "status": "read",
      "dollars1": 47880,
      "fplPct": null
     }
    ],
    "anyLimit": true
   }
  ],
  "medicare": {
   "excluded": 9,
   "allowed": 2,
   "conditional": 8,
   "notPublished": 13
  },
  "sameCompany": [
   {
    "sponsor": "Lilly",
    "oneLimits": [
     47880,
     63840
    ],
    "ratio": 1.33
   },
   {
    "sponsor": "Boehringer Ingelheim",
    "oneLimits": [
     31920,
     39900
    ],
    "ratio": 1.25
   },
   {
    "sponsor": "Merck",
    "oneLimits": [
     63840,
     79800
    ],
    "ratio": 1.25
   }
  ],
  "exempt": [
   "Opdivo"
  ],
  "jnjBelow2026Pct": -1.94
 },
 "checks": [
  {
   "drug": "Trelegy Ellipta",
   "sponsor": "GSK",
   "statedPct": null,
   "dollars1": 47880,
   "impliedPctOfFpl2026": 300,
   "checks": [
    {
     "household": 1,
     "stated": 47880,
     "impliedPct": 300
    },
    {
     "household": 2,
     "stated": 64920,
     "impliedPct": 300
    },
    {
     "household": 3,
     "stated": 81960,
     "impliedPct": 300
    },
    {
     "household": 4,
     "stated": 99000,
     "impliedPct": 300
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Anoro Ellipta",
   "sponsor": "GSK",
   "statedPct": null,
   "dollars1": 47880,
   "impliedPctOfFpl2026": 300,
   "checks": [
    {
     "household": 1,
     "stated": 47880,
     "impliedPct": 300
    },
    {
     "household": 2,
     "stated": 64920,
     "impliedPct": 300
    },
    {
     "household": 3,
     "stated": 81960,
     "impliedPct": 300
    },
    {
     "household": 4,
     "stated": 99000,
     "impliedPct": 300
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Breo Ellipta",
   "sponsor": "GSK",
   "statedPct": null,
   "dollars1": 47880,
   "impliedPctOfFpl2026": 300,
   "checks": [
    {
     "household": 1,
     "stated": 47880,
     "impliedPct": 300
    },
    {
     "household": 2,
     "stated": 64920,
     "impliedPct": 300
    },
    {
     "household": 3,
     "stated": 81960,
     "impliedPct": 300
    },
    {
     "household": 4,
     "stated": 99000,
     "impliedPct": 300
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Eliquis",
   "sponsor": "Bristol Myers Squibb",
   "statedPct": null,
   "dollars1": 47880,
   "impliedPctOfFpl2026": 300,
   "checks": [
    {
     "household": 1,
     "stated": 47880,
     "impliedPct": 300
    },
    {
     "household": 2,
     "stated": 64920,
     "impliedPct": 300
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Jardiance",
   "sponsor": "Boehringer Ingelheim",
   "statedPct": 250,
   "dollars1": 39900,
   "impliedPctOfFpl2026": 250,
   "checks": [
    {
     "household": 1,
     "stated": 39900,
     "recomputed": 39900,
     "match": true
    },
    {
     "household": 2,
     "stated": 54100,
     "recomputed": 54100,
     "match": true
    },
    {
     "household": 3,
     "stated": 68300,
     "recomputed": 68300,
     "match": true
    },
    {
     "household": 4,
     "stated": 82500,
     "recomputed": 82500,
     "match": true
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Tradjenta",
   "sponsor": "Boehringer Ingelheim",
   "statedPct": 250,
   "dollars1": 39900,
   "impliedPctOfFpl2026": 250,
   "checks": [
    {
     "household": 1,
     "stated": 39900,
     "recomputed": 39900,
     "match": true
    },
    {
     "household": 2,
     "stated": 54100,
     "recomputed": 54100,
     "match": true
    },
    {
     "household": 3,
     "stated": 68300,
     "recomputed": 68300,
     "match": true
    },
    {
     "household": 4,
     "stated": 82500,
     "recomputed": 82500,
     "match": true
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Spiriva Respimat",
   "sponsor": "Boehringer Ingelheim",
   "statedPct": 200,
   "dollars1": 31920,
   "impliedPctOfFpl2026": 200,
   "checks": [
    {
     "household": 1,
     "stated": 31920,
     "recomputed": 31920,
     "match": true
    },
    {
     "household": 2,
     "stated": 43280,
     "recomputed": 43280,
     "match": true
    },
    {
     "household": 3,
     "stated": 54640,
     "recomputed": 54640,
     "match": true
    },
    {
     "household": 4,
     "stated": 66000,
     "recomputed": 66000,
     "match": true
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Repatha",
   "sponsor": "Amgen",
   "statedPct": null,
   "dollars1": 47880,
   "impliedPctOfFpl2026": 300,
   "checks": [
    {
     "household": 1,
     "stated": 47880,
     "impliedPct": 300
    },
    {
     "household": 2,
     "stated": 64920,
     "impliedPct": 300
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Otezla",
   "sponsor": "Amgen",
   "statedPct": null,
   "dollars1": 47880,
   "impliedPctOfFpl2026": 300,
   "checks": [
    {
     "household": 1,
     "stated": 47880,
     "impliedPct": 300
    },
    {
     "household": 2,
     "stated": 64920,
     "impliedPct": 300
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Enbrel",
   "sponsor": "Amgen",
   "statedPct": null,
   "dollars1": 47880,
   "impliedPctOfFpl2026": 300,
   "checks": [
    {
     "household": 1,
     "stated": 47880,
     "impliedPct": 300
    },
    {
     "household": 2,
     "stated": 64920,
     "impliedPct": 300
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Trulicity",
   "sponsor": "Lilly",
   "statedPct": 300,
   "dollars1": 47880,
   "impliedPctOfFpl2026": 300,
   "checks": [
    {
     "household": 1,
     "stated": 47880,
     "recomputed": 47880,
     "match": true
    },
    {
     "household": 2,
     "stated": 64920,
     "recomputed": 64920,
     "match": true
    },
    {
     "household": 3,
     "stated": 81960,
     "recomputed": 81960,
     "match": true
    },
    {
     "household": 4,
     "stated": 99000,
     "recomputed": 99000,
     "match": true
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Humalog",
   "sponsor": "Lilly",
   "statedPct": 400,
   "dollars1": 63840,
   "impliedPctOfFpl2026": 400,
   "checks": [
    {
     "household": 1,
     "stated": 63840,
     "recomputed": 63840,
     "match": true
    },
    {
     "household": 2,
     "stated": 86560,
     "recomputed": 86560,
     "match": true
    },
    {
     "household": 3,
     "stated": 109280,
     "recomputed": 109280,
     "match": true
    },
    {
     "household": 4,
     "stated": 132000,
     "recomputed": 132000,
     "match": true
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Xarelto",
   "sponsor": "Johnson & Johnson",
   "statedPct": 300,
   "dollars1": 46950,
   "impliedPctOfFpl2026": 294.17,
   "checks": [
    {
     "household": 1,
     "stated": 46950,
     "recomputed": 47880,
     "match": false
    },
    {
     "household": 2,
     "stated": 63450,
     "recomputed": 64920,
     "match": false
    },
    {
     "household": 3,
     "stated": 79950,
     "recomputed": 81960,
     "match": false
    },
    {
     "household": 4,
     "stated": 96450,
     "recomputed": 99000,
     "match": false
    }
   ],
   "status": "MISMATCH"
  },
  {
   "drug": "Januvia",
   "sponsor": "Merck",
   "statedPct": null,
   "dollars1": 63840,
   "impliedPctOfFpl2026": 400,
   "checks": [
    {
     "household": 1,
     "stated": 63840,
     "impliedPct": 400
    },
    {
     "household": 2,
     "stated": 86560,
     "impliedPct": 400
    },
    {
     "household": 4,
     "stated": 132000,
     "impliedPct": 400
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Keytruda",
   "sponsor": "Merck",
   "statedPct": null,
   "dollars1": 79800,
   "impliedPctOfFpl2026": 500,
   "checks": [
    {
     "household": 1,
     "stated": 79800,
     "impliedPct": 500
    },
    {
     "household": 2,
     "stated": 108200,
     "impliedPct": 500
    },
    {
     "household": 4,
     "stated": 165000,
     "impliedPct": 500
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Lantus",
   "sponsor": "Sanofi",
   "statedPct": 400,
   "dollars1": 63840,
   "impliedPctOfFpl2026": 400,
   "checks": [
    {
     "household": 1,
     "stated": 63840,
     "recomputed": 63840,
     "match": true
    },
    {
     "household": 2,
     "stated": 86560,
     "recomputed": 86560,
     "match": true
    },
    {
     "household": 3,
     "stated": 109280,
     "recomputed": 109280,
     "match": true
    },
    {
     "household": 4,
     "stated": 132000,
     "recomputed": 132000,
     "match": true
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Skyrizi",
   "sponsor": "AbbVie",
   "statedPct": null,
   "dollars1": 63840,
   "impliedPctOfFpl2026": 400,
   "checks": [
    {
     "household": 1,
     "stated": 63840,
     "impliedPct": 400
    },
    {
     "household": 2,
     "stated": 86560,
     "impliedPct": 400
    },
    {
     "household": 3,
     "stated": 109280,
     "impliedPct": 400
    },
    {
     "household": 4,
     "stated": 132000,
     "impliedPct": 400
    }
   ],
   "status": "consistent"
  },
  {
   "drug": "Humira",
   "sponsor": "AbbVie",
   "statedPct": null,
   "dollars1": 63840,
   "impliedPctOfFpl2026": 400,
   "checks": [
    {
     "household": 1,
     "stated": 63840,
     "impliedPct": 400
    },
    {
     "household": 2,
     "stated": 86560,
     "impliedPct": 400
    },
    {
     "household": 3,
     "stated": 109280,
     "impliedPct": 400
    },
    {
     "household": 4,
     "stated": 132000,
     "impliedPct": 400
    }
   ],
   "status": "consistent"
  }
 ],
 "mismatches": [
  {
   "drug": "Xarelto",
   "sponsor": "Johnson & Johnson",
   "statedPct": 300,
   "dollars1": 46950,
   "impliedPctOfFpl2026": 294.17,
   "checks": [
    {
     "household": 1,
     "stated": 46950,
     "recomputed": 47880,
     "match": false
    },
    {
     "household": 2,
     "stated": 63450,
     "recomputed": 64920,
     "match": false
    },
    {
     "household": 3,
     "stated": 79950,
     "recomputed": 81960,
     "match": false
    },
    {
     "household": 4,
     "stated": 96450,
     "recomputed": 99000,
     "match": false
    }
   ],
   "status": "MISMATCH"
  }
 ],
 "dated": [
  {
   "event": "Farxiga removed from AstraZeneca AZ&Me for new patients",
   "effective": "2026-05-01",
   "supportEnds": "2026-12-31",
   "sponsor": "AstraZeneca",
   "sourceUrl": "https://www.azandmeapp.com/important-program-updates"
  },
  {
   "event": "Boehringer Cares stopped accepting new Medicare Part D or Advantage enrollments for primary care products (including Jardiance, Tradjenta, Spiriva Respimat)",
   "effective": "2026-10-15",
   "sponsor": "Boehringer Ingelheim",
   "sourceUrl": "https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/pdf/pap-important-updates"
  },
  {
   "event": "Boehringer Cares Ofev no longer available through the program",
   "effective": "2026-09-11",
   "sponsor": "Boehringer Ingelheim",
   "sourceUrl": "https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/pdf/pap-important-updates"
  },
  {
   "event": "Lilly Cares again accepts new Trulicity applications without a medical exception request",
   "effective": "banner read 2026-10-29",
   "sponsor": "Lilly",
   "sourceUrl": "https://www.lillycares.com/"
  }
 ],
 "rows": [
  {
   "drug": "Ozempic",
   "sponsor": "Novo Nordisk",
   "program": "Novo Nordisk Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "not-published",
   "incomeRule": "none-published",
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "uninsured-only",
   "medicareRule": "excluded",
   "otherConditions": "Product list footnote: available for uninsured patients only. The sponsor page says only \"a total household income that qualifies\" and refers readers to NeedyMeds for poverty guidelines.",
   "applyUrl": "https://www.novocare.com/diabetes/help-with-costs/pap.html",
   "sourceUrl": "https://www.novocare.com/content/dam/novonordisk/novocare/forms/PAP_Product_List.pdf",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshot of product list PDF (NNIPAP_11_01012026) and page text"
  },
  {
   "drug": "Wegovy",
   "sponsor": "Novo Nordisk",
   "program": "Novo Nordisk Patient Assistance Program",
   "listedAsCovered": "no",
   "rowStatus": "not-listed",
   "incomeRule": null,
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "not-published",
   "medicareRule": "not-published",
   "otherConditions": "Not on the program's available-products list.",
   "applyUrl": "https://www.novocare.com/diabetes/help-with-costs/pap.html",
   "sourceUrl": "https://www.novocare.com/content/dam/novonordisk/novocare/forms/PAP_Product_List.pdf",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshot of product list PDF"
  },
  {
   "drug": "Rybelsus",
   "sponsor": "Novo Nordisk",
   "program": "Novo Nordisk Patient Assistance Program",
   "listedAsCovered": "no",
   "rowStatus": "not-listed",
   "incomeRule": null,
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "not-published",
   "medicareRule": "not-published",
   "otherConditions": "Not on the program's available-products list.",
   "applyUrl": "https://www.novocare.com/diabetes/help-with-costs/pap.html",
   "sourceUrl": "https://www.novocare.com/content/dam/novonordisk/novocare/forms/PAP_Product_List.pdf",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshot of product list PDF"
  },
  {
   "drug": "Tresiba",
   "sponsor": "Novo Nordisk",
   "program": "Novo Nordisk Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "not-published",
   "incomeRule": "none-published",
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "allowed-with-conditions",
   "otherConditions": "Private or commercial insurance is not eligible. Medicare patients need a Low Income Subsidy denial letter if LIS-eligible. No percentage or dollar limit appears on the sponsor page, product list or application page 1.",
   "applyUrl": "https://www.novocare.com/diabetes/help-with-costs/pap.html",
   "sourceUrl": "https://www.novocare.com/diabetes/help-with-costs/pap.html",
   "readDate": "2026-10-29",
   "evidenceSha256": "33ba24c62fbd4d3661f730bbc711b5bd09b09e3222cef1500d86db399b94a931",
   "evidenceMethod": "page text hash with sections expanded; product list read as screenshot"
  },
  {
   "drug": "NovoLog",
   "sponsor": "Novo Nordisk",
   "program": "Novo Nordisk Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "not-published",
   "incomeRule": "none-published",
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "allowed-with-conditions",
   "otherConditions": "Private or commercial insurance is not eligible. Medicare patients need a Low Income Subsidy denial letter if LIS-eligible. No percentage or dollar limit appears on the sponsor page, product list or application page 1.",
   "applyUrl": "https://www.novocare.com/diabetes/help-with-costs/pap.html",
   "sourceUrl": "https://www.novocare.com/diabetes/help-with-costs/pap.html",
   "readDate": "2026-10-29",
   "evidenceSha256": "33ba24c62fbd4d3661f730bbc711b5bd09b09e3222cef1500d86db399b94a931",
   "evidenceMethod": "page text hash with sections expanded; product list read as screenshot"
  },
  {
   "drug": "Trelegy Ellipta",
   "sponsor": "GSK",
   "program": "GSK Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars, Medicare Part D path, 48 states and DC (Alaska, Hawaii and Puerto Rico have separate tables)",
   "fplPct": null,
   "dollars1": 47880,
   "dollars2": 64920,
   "dollars3": 81960,
   "dollars4": 99000,
   "perExtraPerson": 17040,
   "basisYear": 2026,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "allowed-with-conditions",
   "otherConditions": "Figures are the Medicare Part D path table; the sponsor page for uninsured patients states only \"financial income eligibility criteria\". Medicare patients must have paid $600 for prescriptions in the current calendar year.",
   "applyUrl": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/",
   "sourceUrl": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/medicare/",
   "readDate": "2026-10-29",
   "evidenceSha256": "d342140bea319fd0f025ba3ad5841ce0ff77388ab9bea1c101e6bb4af4f6a064",
   "evidenceMethod": "page text hash; drug list read through the sponsor's own medicine lookup box"
  },
  {
   "drug": "Anoro Ellipta",
   "sponsor": "GSK",
   "program": "GSK Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars, Medicare Part D path, 48 states and DC (Alaska, Hawaii and Puerto Rico have separate tables)",
   "fplPct": null,
   "dollars1": 47880,
   "dollars2": 64920,
   "dollars3": 81960,
   "dollars4": 99000,
   "perExtraPerson": 17040,
   "basisYear": 2026,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "allowed-with-conditions",
   "otherConditions": "Figures are the Medicare Part D path table; the sponsor page for uninsured patients states only \"financial income eligibility criteria\". Medicare patients must have paid $600 for prescriptions in the current calendar year.",
   "applyUrl": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/",
   "sourceUrl": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/medicare/",
   "readDate": "2026-10-29",
   "evidenceSha256": "d342140bea319fd0f025ba3ad5841ce0ff77388ab9bea1c101e6bb4af4f6a064",
   "evidenceMethod": "page text hash; drug list read through the sponsor's own medicine lookup box"
  },
  {
   "drug": "Breo Ellipta",
   "sponsor": "GSK",
   "program": "GSK Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars, Medicare Part D path, 48 states and DC (Alaska, Hawaii and Puerto Rico have separate tables)",
   "fplPct": null,
   "dollars1": 47880,
   "dollars2": 64920,
   "dollars3": 81960,
   "dollars4": 99000,
   "perExtraPerson": 17040,
   "basisYear": 2026,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "allowed-with-conditions",
   "otherConditions": "Figures are the Medicare Part D path table; the sponsor page for uninsured patients states only \"financial income eligibility criteria\". Medicare patients must have paid $600 for prescriptions in the current calendar year.",
   "applyUrl": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/",
   "sourceUrl": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/medicare/",
   "readDate": "2026-10-29",
   "evidenceSha256": "d342140bea319fd0f025ba3ad5841ce0ff77388ab9bea1c101e6bb4af4f6a064",
   "evidenceMethod": "page text hash; drug list read through the sponsor's own medicine lookup box"
  },
  {
   "drug": "Farxiga",
   "sponsor": "AstraZeneca",
   "program": "AZ&Me Prescription Savings Program",
   "listedAsCovered": "no",
   "rowStatus": "not-listed",
   "incomeRule": null,
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "not-published",
   "medicareRule": "not-published",
   "otherConditions": "Removed from AZ&Me: from 2026-05-01 no new patients; enrolled patients supported until 2026-12-31. Reason stated: generic equivalents available since April 2026.",
   "applyUrl": "https://www.azandmeapp.com/eligibility-requirements",
   "sourceUrl": "https://www.azandmeapp.com/important-program-updates",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshot of expanded notice on the program updates page"
  },
  {
   "drug": "Symbicort",
   "sponsor": "AstraZeneca",
   "program": "AZ&Me Prescription Savings Program",
   "listedAsCovered": "no",
   "rowStatus": "not-listed",
   "incomeRule": null,
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "not-published",
   "medicareRule": "not-published",
   "otherConditions": "Not among the 15 products on the program medications page (Airsupra, Baxfendy, Bevespi, Breztri, Lokelma, Calquence, Etcamah, Fasenra, Imfinzi, Imjudo, Lynparza, Saphnelo, Tagrisso, Truqap, Wainua). Read in v1.1.",
   "applyUrl": "https://www.azandmeapp.com/eligibility-requirements",
   "sourceUrl": "https://www.azandmeapp.com/included-medications",
   "readDate": "2026-10-30",
   "evidenceSha256": null,
   "evidenceMethod": "page text and product logo alt text"
  },
  {
   "drug": "Brilinta",
   "sponsor": "AstraZeneca",
   "program": "AZ&Me Prescription Savings Program",
   "listedAsCovered": "no",
   "rowStatus": "not-listed",
   "incomeRule": null,
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "not-published",
   "medicareRule": "not-published",
   "otherConditions": "Not among the 15 products on the program medications page. Read in v1.1.",
   "applyUrl": "https://www.azandmeapp.com/eligibility-requirements",
   "sourceUrl": "https://www.azandmeapp.com/included-medications",
   "readDate": "2026-10-30",
   "evidenceSha256": null,
   "evidenceMethod": "page text and product logo alt text"
  },
  {
   "drug": "Eliquis",
   "sponsor": "Bristol Myers Squibb",
   "program": "Bristol Myers Squibb Patient Assistance Foundation",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars for Eliquis and Orencia; adjusted for larger families",
   "fplPct": null,
   "dollars1": 47880,
   "dollars2": 64920,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": 2026,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "allowed-with-conditions",
   "otherConditions": "No insurance coverage for the medicine, or Medicare with at least 3% of yearly household income spent on out-of-pocket prescriptions in the same calendar year. Age 65 and over must not qualify for Part D Low Income Subsidy (proof of denial). Medicaid-eligible patients must submit proof of denial.",
   "applyUrl": "https://www.bmspaf.org/#/apply",
   "sourceUrl": "https://www.bmspaf.org/#/eligibility",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text of eligibility and medicines pages"
  },
  {
   "drug": "Eliquis",
   "sponsor": "Pfizer",
   "program": "Pfizer RxPathways Patient Assistance Program",
   "listedAsCovered": "ambiguous",
   "rowStatus": "blocked",
   "incomeRule": "fpl-pct",
   "incomeBasis": "program-wide 300% FPL stated on the sponsor updates page; Eliquis listing not confirmed (the product list sits behind an application flow, not entered)",
   "fplPct": 300,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": 2026,
   "insuranceRule": "not-published",
   "medicareRule": "not-published",
   "otherConditions": "Row status blocked because Pfizer's own list could not be read without starting an application. The 300% program limit is recorded for context only.",
   "applyUrl": "https://www.pfizerrxpathways.com/find-program",
   "sourceUrl": "https://www.pfizerrxpathways.com/updates",
   "readDate": "2026-10-29",
   "evidenceSha256": "64a98a8135303dcdf304ba39e9961bf7e21fb215564dbb909f631ec87837a164",
   "evidenceMethod": "page text hash of updates page"
  },
  {
   "drug": "Opdivo",
   "sponsor": "Bristol Myers Squibb",
   "program": "Bristol Myers Squibb Patient Assistance Foundation",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "exempt",
   "incomeBasis": "BMS states cancer medicines qualify even when income is higher than the Eliquis and Orencia limits",
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "allowed-with-conditions",
   "otherConditions": "On the available-medicines list. No income cap is stated for BMS cancer medicines; the same insurance and Medicare rules apply.",
   "applyUrl": "https://www.bmspaf.org/#/apply",
   "sourceUrl": "https://www.bmspaf.org/#/eligibility",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text of eligibility and medicines pages"
  },
  {
   "drug": "Jardiance",
   "sponsor": "Boehringer Ingelheim",
   "program": "Boehringer Cares Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "fpl-pct",
   "incomeBasis": "250% FPL, \"all other medications\" group, 48 states (Alaska and Hawaii higher)",
   "fplPct": 250,
   "dollars1": 39900,
   "dollars2": 54100,
   "dollars3": 68300,
   "dollars4": 82500,
   "perExtraPerson": null,
   "basisYear": 2026,
   "insuranceRule": "uninsured-only",
   "medicareRule": "excluded",
   "otherConditions": "Effective 2026-10-15 the program accepts no new Medicare Part D or Advantage enrollments for this primary care product; insured patients whose insurance covers the medicine are not eligible. Document code NP-US-100242 (09/2026). Group assignment inferred: the drug is not in the Respimat heading.",
   "applyUrl": "https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/boehringer-cares-patient-assistance-portal",
   "sourceUrl": "https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/pdf/patient-assistance-program-eligibility-information",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshots of PDF pages 1 to 3"
  },
  {
   "drug": "Tradjenta",
   "sponsor": "Boehringer Ingelheim",
   "program": "Boehringer Cares Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "fpl-pct",
   "incomeBasis": "250% FPL, \"all other medications\" group, 48 states (Alaska and Hawaii higher)",
   "fplPct": 250,
   "dollars1": 39900,
   "dollars2": 54100,
   "dollars3": 68300,
   "dollars4": 82500,
   "perExtraPerson": null,
   "basisYear": 2026,
   "insuranceRule": "uninsured-only",
   "medicareRule": "excluded",
   "otherConditions": "Effective 2026-10-15 the program accepts no new Medicare Part D or Advantage enrollments for this primary care product; insured patients whose insurance covers the medicine are not eligible. Document code NP-US-100242 (09/2026). Group assignment inferred: the drug is not in the Respimat heading.",
   "applyUrl": "https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/boehringer-cares-patient-assistance-portal",
   "sourceUrl": "https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/pdf/patient-assistance-program-eligibility-information",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshots of PDF pages 1 to 3"
  },
  {
   "drug": "Spiriva Respimat",
   "sponsor": "Boehringer Ingelheim",
   "program": "Boehringer Cares Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "fpl-pct",
   "incomeBasis": "200% FPL, Combivent, Spiriva and Stiolto Respimat group, 48 states (Alaska and Hawaii higher)",
   "fplPct": 200,
   "dollars1": 31920,
   "dollars2": 43280,
   "dollars3": 54640,
   "dollars4": 66000,
   "perExtraPerson": null,
   "basisYear": 2026,
   "insuranceRule": "uninsured-only",
   "medicareRule": "excluded",
   "otherConditions": "Effective 2026-10-15 the program accepts no new Medicare Part D or Advantage enrollments for this primary care product. Document code NP-US-100242 (09/2026).",
   "applyUrl": "https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/boehringer-cares-patient-assistance-portal",
   "sourceUrl": "https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/pdf/patient-assistance-program-eligibility-information",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshots of PDF pages 1 to 3"
  },
  {
   "drug": "Repatha",
   "sponsor": "Amgen",
   "program": "Amgen Safety Net Foundation",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars on the sponsor's product application",
   "fplPct": null,
   "dollars1": 47880,
   "dollars2": 64920,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": 17040,
   "basisYear": 2026,
   "insuranceRule": "uninsured-only",
   "medicareRule": "excluded",
   "otherConditions": "Application states no insurance coverage. The sponsor eligibility page says certain products accept Medicare patients with an affordability gap; this product's application does not.",
   "applyUrl": "https://www.amgensafetynetfoundation.com/eligibility.html",
   "sourceUrl": "https://www.amgensafetynetfoundation.com/assets/pdf/AMGEN-SNF-Application-Prescription-Repatha-EN.pdf",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshot of the product application PDF, page 1"
  },
  {
   "drug": "Otezla",
   "sponsor": "Amgen",
   "program": "Amgen Safety Net Foundation",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars on the sponsor's product application",
   "fplPct": null,
   "dollars1": 47880,
   "dollars2": 64920,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": 17040,
   "basisYear": 2026,
   "insuranceRule": "uninsured-only",
   "medicareRule": "excluded",
   "otherConditions": "Application states no insurance coverage. The sponsor eligibility page says certain products accept Medicare patients with an affordability gap; this product's application does not.",
   "applyUrl": "https://www.amgensafetynetfoundation.com/eligibility.html",
   "sourceUrl": "https://www.amgensafetynetfoundation.com/assets/pdf/AMGEN-SNF-Application-Prescription-Otezla-EN.pdf",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshot of the product application PDF, page 1"
  },
  {
   "drug": "Enbrel",
   "sponsor": "Amgen",
   "program": "Amgen Safety Net Foundation",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars on the sponsor's product application",
   "fplPct": null,
   "dollars1": 47880,
   "dollars2": 64920,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": 17040,
   "basisYear": 2026,
   "insuranceRule": "uninsured-only",
   "medicareRule": "excluded",
   "otherConditions": "Application states no insurance coverage. The sponsor eligibility page says certain products accept Medicare patients with an affordability gap; this product's application does not.",
   "applyUrl": "https://www.amgensafetynetfoundation.com/eligibility.html",
   "sourceUrl": "https://www.amgensafetynetfoundation.com/assets/pdf/AMGEN-SNF-Application-Prescription-Enbrel-EN.pdf",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshot of the product application PDF, page 1"
  },
  {
   "drug": "Mounjaro",
   "sponsor": "Lilly",
   "program": "Lilly Cares Foundation Patient Assistance Program",
   "listedAsCovered": "no",
   "rowStatus": "not-listed",
   "incomeRule": null,
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "not-published",
   "medicareRule": "not-published",
   "otherConditions": "Not on the Lilly Cares available-medications list.",
   "applyUrl": "https://www.lillycares.com/how-to-apply",
   "sourceUrl": "https://www.lillycares.com/available-medications",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  },
  {
   "drug": "Zepbound",
   "sponsor": "Lilly",
   "program": "Lilly Cares Foundation Patient Assistance Program",
   "listedAsCovered": "no",
   "rowStatus": "not-listed",
   "incomeRule": null,
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "not-published",
   "medicareRule": "not-published",
   "otherConditions": "Not on the Lilly Cares available-medications list.",
   "applyUrl": "https://www.lillycares.com/how-to-apply",
   "sourceUrl": "https://www.lillycares.com/available-medications",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  },
  {
   "drug": "Trulicity",
   "sponsor": "Lilly",
   "program": "Lilly Cares Foundation Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "fpl-pct",
   "incomeBasis": "300% FPL, Group 1 medications",
   "fplPct": 300,
   "dollars1": 47880,
   "dollars2": 64920,
   "dollars3": 81960,
   "dollars4": 99000,
   "perExtraPerson": 17040,
   "basisYear": 2026,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "allowed",
   "otherConditions": "No insurance or Medicare Part D. Not eligible if enrolled in Medicaid, full Low Income Subsidy or VA benefits. Alaska and Hawaii: contact the program. Banner: new Trulicity applications again accepted without a medical exception request.",
   "applyUrl": "https://www.lillycares.com/how-to-apply",
   "sourceUrl": "https://www.lillycares.com/how-to-apply",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  },
  {
   "drug": "Humalog",
   "sponsor": "Lilly",
   "program": "Lilly Cares Foundation Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "fpl-pct",
   "incomeBasis": "400% FPL, Group 2 medications",
   "fplPct": 400,
   "dollars1": 63840,
   "dollars2": 86560,
   "dollars3": 109280,
   "dollars4": 132000,
   "perExtraPerson": 22720,
   "basisYear": 2026,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "allowed",
   "otherConditions": "No insurance or Medicare Part D. Not eligible if enrolled in Medicaid, full Low Income Subsidy or VA benefits. Alaska and Hawaii: contact the program.",
   "applyUrl": "https://www.lillycares.com/how-to-apply",
   "sourceUrl": "https://www.lillycares.com/how-to-apply",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  },
  {
   "drug": "Xarelto",
   "sponsor": "Johnson & Johnson",
   "program": "Johnson & Johnson Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "fpl-pct",
   "incomeBasis": "300% FPL; the guide's \"2026 Program Income Limit\" table, all states except Alaska and Hawaii",
   "fplPct": 300,
   "dollars1": 46950,
   "dollars2": 63450,
   "dollars3": 79950,
   "dollars4": 96450,
   "perExtraPerson": 16500,
   "basisYear": 2025,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "allowed-with-conditions",
   "otherConditions": "The table is labelled 2026 but its one-person figure equals 300% of the 2025 guideline ($15,650); 300% of the 2026 guideline is $47,880. Medicare Part D patients must show they are not eligible for Low Income Subsidy (applies at or below 150% FPL). Stelara, Tremfya and Imbruvica are not on this guide.",
   "applyUrl": "https://www.jjpatientassistance.com/",
   "sourceUrl": "https://asset.jnjwithme.com/document/JnJ_Patient_Assistance_Quick_Reference_Guide_Other_Medications.pdf",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "screenshots of PDF pages 1 and 2"
  },
  {
   "drug": "Januvia",
   "sponsor": "Merck",
   "program": "Merck Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars for individuals, couples and a family of 4",
   "fplPct": null,
   "dollars1": 63840,
   "dollars2": 86560,
   "dollars3": null,
   "dollars4": 132000,
   "perExtraPerson": null,
   "basisYear": 2026,
   "insuranceRule": "uninsured-only",
   "medicareRule": "excluded",
   "otherConditions": "No private insurance, HMO, Medicaid, Medicare, state pharmacy assistance or VA coverage; an exception route exists with attested financial and medical hardship if income meets the criteria. Alaska and Hawaii: call the program.",
   "applyUrl": "https://www.merckhelps.com/how-to-apply",
   "sourceUrl": "https://www.merckhelps.com/JANUVIA",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  },
  {
   "drug": "Keytruda",
   "sponsor": "Merck",
   "program": "Merck Patient Assistance Program",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars for individuals, couples and a family of 4",
   "fplPct": null,
   "dollars1": 79800,
   "dollars2": 108200,
   "dollars3": null,
   "dollars4": 165000,
   "perExtraPerson": null,
   "basisYear": 2026,
   "insuranceRule": "uninsured-only",
   "medicareRule": "excluded",
   "otherConditions": "No private insurance, HMO, Medicaid, Medicare, state pharmacy assistance or VA coverage; an exception route exists with attested financial and medical hardship if income meets the criteria. Alaska and Hawaii: call the program.",
   "applyUrl": "https://www.merckhelps.com/how-to-apply",
   "sourceUrl": "https://www.merckhelps.com/KEYTRUDA",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  },
  {
   "drug": "Dupixent",
   "sponsor": "Sanofi",
   "program": "Sanofi Patient Connection (Patient Assistance Connection)",
   "listedAsCovered": "no",
   "rowStatus": "not-listed",
   "incomeRule": null,
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "not-published",
   "medicareRule": "not-published",
   "otherConditions": "Not on the Sanofi Patient Connection medications-available list. Dupixent has its own support program, which was not read.",
   "applyUrl": "https://www.sanofipatientconnection.com/patient-assistance-connection",
   "sourceUrl": "https://www.sanofipatientconnection.com/medications-available",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  },
  {
   "drug": "Lantus",
   "sponsor": "Sanofi",
   "program": "Sanofi Patient Connection (Patient Assistance Connection)",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "fpl-pct",
   "incomeBasis": "400% FPL, 48 states and DC (Alaska and Hawaii tables published)",
   "fplPct": 400,
   "dollars1": 63840,
   "dollars2": 86560,
   "dollars3": 109280,
   "dollars4": 132000,
   "perExtraPerson": 22720,
   "basisYear": 2026,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "not-published",
   "otherConditions": "Applies to uninsured or functionally uninsured patients. Sanofi prints the HHS 2026 guideline tables on the same page.",
   "applyUrl": "https://www.sanofipatientconnection.com/patient-assistance-connection",
   "sourceUrl": "https://www.sanofipatientconnection.com/financial-eligibility",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  },
  {
   "drug": "Entresto",
   "sponsor": "Novartis",
   "program": "Novartis Patient Assistance Foundation",
   "listedAsCovered": "no",
   "rowStatus": "not-listed",
   "incomeRule": null,
   "incomeBasis": null,
   "fplPct": null,
   "dollars1": null,
   "dollars2": null,
   "dollars3": null,
   "dollars4": null,
   "perExtraPerson": null,
   "basisYear": null,
   "insuranceRule": "not-published",
   "medicareRule": "not-published",
   "otherConditions": "Not on the Novartis Patient Assistance Foundation medications list. The foundation page states \"meet income guidelines\" with no figure.",
   "applyUrl": "https://pap.novartis.com/",
   "sourceUrl": "https://pap.novartis.com/medications-list/",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  },
  {
   "drug": "Skyrizi",
   "sponsor": "AbbVie",
   "program": "myAbbVie Assist",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars, household size 1 to 4",
   "fplPct": null,
   "dollars1": 63840,
   "dollars2": 86560,
   "dollars3": 109280,
   "dollars4": 132000,
   "perExtraPerson": 22720,
   "basisYear": 2026,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "not-published",
   "otherConditions": "Limited or no health insurance and demonstrated financial need; alternate funding program patients excluded. Skyrizi is on the returning-patient medicines list on the program page.",
   "applyUrl": "https://www.abbvie.com/patients/patient-support/patient-assistance.html",
   "sourceUrl": "https://www.abbvie.com/patients/patient-support/patient-assistance/income-criteria.html",
   "readDate": "2026-10-29",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  },
  {
   "drug": "Humira",
   "sponsor": "AbbVie",
   "program": "myAbbVie Assist",
   "listedAsCovered": "yes",
   "rowStatus": "read",
   "incomeRule": "dollars",
   "incomeBasis": "dollars, household size 1 to 4",
   "fplPct": null,
   "dollars1": 63840,
   "dollars2": 86560,
   "dollars3": 109280,
   "dollars4": 132000,
   "perExtraPerson": 22720,
   "basisYear": 2026,
   "insuranceRule": "uninsured-or-underinsured",
   "medicareRule": "not-published",
   "otherConditions": "Limited or no health insurance and demonstrated financial need; alternate funding program patients excluded. Humira is on the full available-medicines list (available-programs page, read 2026-10-30); v1.0 had it blocked because only the returning-patient list had been read.",
   "applyUrl": "https://www.abbvie.com/patients/patient-support/patient-assistance.html",
   "sourceUrl": "https://www.abbvie.com/patients/patient-support/patient-assistance/income-criteria.html",
   "readDate": "2026-10-30",
   "evidenceSha256": null,
   "evidenceMethod": "page text"
  }
 ]
}